Nabriva Therapeutics AG - Stock Price History | NBRV

Historical daily share price chart and data for Nabriva Therapeutics AG since 2021 adjusted for splits. The latest closing stock price for Nabriva Therapeutics AG as of October 22, 2021 is 1.09.
  • The all-time high Nabriva Therapeutics AG stock closing price was 132.40 on September 18, 2015.
  • The Nabriva Therapeutics AG 52-week high stock price is 5.70, which is 422.9% above the current share price.
  • The Nabriva Therapeutics AG 52-week low stock price is 1.00, which is 8.3% below the current share price.
  • The average Nabriva Therapeutics AG stock price for the last 52 weeks is 2.06.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Nabriva Therapeutics AG Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 7.4471 13.2000 16.2000 2.3700 2.4200 -81.67%
2019 21.8024 16.8000 31.7000 12.8000 13.2000 -9.59%
2018 38.5717 63.6000 68.6000 12.0000 14.6000 -75.59%
2017 89.3867 62.9000 126.2000 51.0000 59.8000 0.34%
2016 74.1487 95.1500 95.1500 40.0000 59.6000 -38.05%
2015 98.6195 132.4000 132.4000 86.6000 96.2000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.560B $0.005B
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57